Navigation Links
Reducing Vertebral Fractures In Women

Vertebral fractures are a serious consequence of osteoporosis. Such a break can lead to acute and chronic back pain,// spinal deformity and hip fracture.

According to a recent study , it was found that the drug strontium ranelate, for women with osteoporosis appears to be effective in reducing the risk for a vertebral fracture, according to new research. The study also reports that the drug can reduce the risk of breaking a bone in the vertebral column by 49 percent.

Researchers in France conducted a larger study to compare the drug to placebo in postmenopausal women with osteoporosis.The study included 1,649 postmenopausal women with osteoporosis and who suffered at least one vertebral fracture. The women received either the drug strontium ranelate or a placebo daily for three years. Participants were also given calcium and vitamin D supplements. Vertebral radiographs were done each year and measurements of bone mineral density were performed every six months.

Researchers report new vertebral fractures occurred in fewer patients in the strontium ranelate group than in the placebo group. Specifically, patients on the drug had 49-percent reduced risk in the first year of treatment and a 41-percent reduction during the three-year study. Researchers say at the end of the study the women on the drug had an increase in their bone mineral density including a 14.4 percent increase at the lumbar spine and 8.3 percent at the femoral neck.

Thus researchers conclude that strontium ranelate given orally each day appears to reduce the risk of vertebral fractures rapidly, effectively and safely among postmenopausal women with osteoporosis.
'"/>




Page: 1

Related medicine news :

1. Reducing Lung Cancer Risk
2. Reducing the risk for type 2 diabetes
3. Reducing Medication Errors
4. Reducing HIV Transmission
5. Reducing Pain from Knee Surgery
6. Reducing Pain From Knee Surgery
7. Reducing The After Effects of Tonsillectomy
8. Antiparasitic Drug Effective In Reducing Seizures In Neurocysticercosis Patients
9. Reducing Number Of Cigarettes Not Enough
10. Drug Found Effective In Reducing Vertebral Fractures In Women
11. Reducing TB With Ultraviolet Light
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: